Trevi Therapeutics Inc’s Quiet Period Set To Expire Tomorrow (NASDAQ:TRVI)

Trevi Therapeutics’ (NASDAQ:TRVI) quiet period will expire on Monday, June 17th. Trevi Therapeutics had issued 5,500,000 shares in its public offering on May 7th. The total size of the offering was $55,000,000 based on an initial share price of $10.00. During the company’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

TRVI has been the topic of several analyst reports. Stifel Nicolaus initiated coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They set a “buy” rating and a $20.00 price target on the stock. Svb Leerink initiated coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They set an “outperform” rating and a $14.00 price target on the stock. BMO Capital Markets initiated coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They set an “outperform” rating and a $15.00 price target on the stock. Leerink Swann initiated coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They set an “outperform” rating on the stock. Finally, Needham & Company LLC initiated coverage on Trevi Therapeutics in a research report on Monday, June 3rd. They set a “buy” rating and a $18.00 price target on the stock. Five analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $16.75.

Shares of TRVI opened at $7.55 on Friday. Trevi Therapeutics has a fifty-two week low of $7.18 and a fifty-two week high of $10.62.



In other Trevi Therapeutics news, insider Jennifer L. Good bought 11,250 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $112,500.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Anne Vanlent bought 5,000 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $50,000.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 391,250 shares of company stock worth $3,912,500 over the last ninety days.

TRADEMARK VIOLATION NOTICE: “Trevi Therapeutics Inc’s Quiet Period Set To Expire Tomorrow (NASDAQ:TRVI)” was originally reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://dakotafinancialnews.com/2019/06/16/trevi-therapeutics-incs-quiet-period-set-to-expire-tomorrow-nasdaqtrvi.html.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Featured Article: Recession

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.